Characteristics and prognostic risk factors of patients with sequence type 5 lineage-associated cryptococcosis in China

Int J Infect Dis. 2023 Mar:128:244-253. doi: 10.1016/j.ijid.2023.01.015. Epub 2023 Jan 14.

Abstract

Objectives: Cryptococcus neoformans sequence type 5 (ST5) lineage could infect immunocompetent hosts and cause a significant medical burden. We sought to identify characteristics and prognostic risk factors of ST5 lineage-associated cryptococcosis.

Methods: Multilocus sequence typing and antifungal susceptibility testing were conducted for Cryptococcus isolates. The clinical and laboratory characteristics of cryptococcosis patients were investigated. The multivariable logistic regression identified variables independently associated with 30-day mortality in patients with ST5 lineage-associated cryptococcosis without HIV.

Results: The infection rate of the ST5 isolates was 89.4% (370/414) in China. The proportion of ST5 isolates with nonwild-type minimum inhibitory concentrations to amphotericin B, 5-flucytosine, voriconazole, posaconazole, itraconazole, and fluconazole were 0%, 5.4%, 0.3%, 1.4%, 0.3%, and 8.1%, respectively. The ST5 lineage-infected group exhibited significantly higher blood platelet count, lower blood cryptococcal antigen (CrAg) titer, lower cerebrospinal fluid (CSF) CrAg titer than the non-ST5 lineage-infected group, and lower hemoglobin and lower CSF CrAg titer than the Cryptococcus gattii isolates-infected group. Seven baseline parameters, including underlying disease, dyskinesia, anemia, high peripheral blood neutrophils, low platelet count, high CSF fungal burden, and high CSF opening pressure, were associated independently with the 30-day mortality of patients with ST5 lineage-associated cryptococcosis without HIV.

Conclusion: Our study has provided an understanding of the ST5 lineage associated with cryptococcosis.

Keywords: Characteristics; Cryptococcosis; Mortality (predictors); ST5 lineage.

MeSH terms

  • Antifungal Agents / pharmacology
  • China
  • Cryptococcosis*
  • Cryptococcus gattii*
  • Cryptococcus neoformans*
  • Genotype
  • HIV Infections* / complications
  • Humans
  • Microbial Sensitivity Tests
  • Prognosis
  • Risk Factors

Substances

  • Antifungal Agents